Skip to main content

CORRECTION article

Front. Oncol., 27 June 2023
Sec. Cancer Molecular Targets and Therapeutics
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1218746

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

Wei-Wei Zuo,&#x;Wei-Wei Zuo1,2†Chun-Fang Zhao&#x;Chun-Fang Zhao3†Yan LiYan Li4Hai-Yan SunHai-Yan Sun1Guo-Ming MaGuo-Ming Ma5Yue-Ping LiuYue-Ping Liu6Shan Kang*Shan Kang1*
  • 1Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China
  • 2Department of Gynecology, Tangshan People’s Hospital, Tangshan, China
  • 3Department of Histoplasty and Embryology, Hebei Medical University, Shijiazhuang, China
  • 4Department of Molecular Biology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China
  • 5Department of gastrointestinal surgery, Tangshan People’s Hospital, Tangshan, China
  • 6Department of Pathology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China

A Corrigendum on
High expression of PARP1 in tumor and stroma cells predicts different prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

by Zuo W-W, Zhao C-F, Li Y, Sun H-Y, Ma G-M, Liu Y-P and Kang S (2022) Front. Oncol. 12:931445. doi: 10.3389/fonc.2022.931445

In the published article, there was an error in the Funding statement. The Grant number for the Natural Science Foundation of Hebei Province was displayed as “H20202063”. The correct Funding statement appears below.

The correct Funding statement is “This work was supported by grants from the Natural Science Foundation of Hebei Province (Grant number: H2020206385).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: advanced epithelial ovarian cancer, PARP1, cytokeratin, platinum resistance, prognosis

Citation: Zuo W-W, Zhao C-F, Li Y, Sun H-Y, Ma G-M, Liu Y-P and Kang S (2023) Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer. Front. Oncol. 13:1218746. doi: 10.3389/fonc.2023.1218746

Received: 08 May 2023; Accepted: 16 May 2023;
Published: 27 June 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Zuo, Zhao, Li, Sun, Ma, Liu and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shan Kang, ksjq62cn@sina.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.